Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Zafgen (ZFGN) Resumes Trading, Down 29%
March 11, 2019 4:36 PM EDTZafgen (NASDAQ: ZFGN) Resumes Trading, Down 29%
... MoreZafgen (ZFGN) reports Q4 loss per share of 39c, to suspend plans to file IND application for ZGN-1258
March 11, 2019 4:11 PM EDT(Updated - March 11, 2019 4:11 PM EDT)
Zafgen (NASDAQ: ZFGN) reported Q4 EPS of ($0.39), $0.09 better than last year.
Zafgen is also announcing its decision to suspend plans to file an investigational new drug (IND) application for ZGN-1258, the Companys candidate for rare metabolic disorders including Prader-Willi syndrome (PWS), based on a recent, unexpected finding in muscle tissue in four- and six-month long-term rodent toxicology studies. Nonclinical data showed degeneration and other anomalies in rat muscle tissue to different degrees in both vehicle and dose arms of the studies. The effects were... More
